Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 11;13(10):1506.
doi: 10.3390/biom13101506.

Association between Impaired Ketogenesis and Metabolic-Associated Fatty Liver Disease

Jaehyun Bae  1 , Byung-Wan Lee  2
Affiliations
Review

Association between Impaired Ketogenesis and Metabolic-Associated Fatty Liver Disease

Jaehyun Bae et al. Biomolecules. .

Abstract

Metabolic (dysfunction) associated fatty liver disease (MAFLD) is generally developed with excessive accumulation of lipids in the liver. Ketogenesis is an efficient pathway for the disposal of fatty acids in the liver and its metabolic benefits have been reported. In this review, we examined previous studies on the association between ketogenesis and MAFLD and reviewed the candidate mechanisms that can explain this association.

Keywords: ketogenesis; ketone; metabolic-associated fatty liver disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic diagram of the ketogenic pathway and its regulators. (+), activation; (−), inhibition; βHB, β-hydroxybutyrate; 3-KT, 3-ketothiolase; ACC, acetyl-CoA carboxylase; CPT, carnitine palmitoyltransferase (carnitine shuttle); HMGCS, mitochondrial HMG-CoA synthase; TCA, tricarboxylic acid.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. McGarry J.D., Foster D.W. Regulation of hepatic fatty acid oxidation and ketone body production. Annu. Rev. Biochem. 1980;49:395–420. doi: 10.1146/annurev.bi.49.070180.002143. - DOI - PubMed
    1. Astrup A., Meinert Larsen T., Harper A. Atkins and other low-carbohydrate diets: Hoax or an effective tool for weight loss? Lancet. 2004;364:897–899. doi: 10.1016/S0140-6736(04)16986-9. - DOI - PubMed
    1. Prattichizzo F., De Nigris V., Micheloni S., La Sala L., Ceriello A. Increases in circulating levels of ketone bodies and cardiovascular protection with sglt2 inhibitors: Is low-grade inflammation the neglected component? Diabetes Obes. Metab. 2018;20:2515–2522. doi: 10.1111/dom.13488. - DOI - PubMed
    1. Ferrannini E., Mark M., Mayoux E. Cv protection in the empa-reg outcome trial: A “thrifty substrate” hypothesis. Diabetes Care. 2016;39:1108–1114. doi: 10.2337/dc16-0330. - DOI - PubMed
    1. Ferrannini E. Sodium-glucose co-transporters and their inhibition: Clinical physiology. Cell Metab. 2017;26:27–38. doi: 10.1016/j.cmet.2017.04.011. - DOI - PubMed

Grants and funding

This study received no external funding.